RE:Thrm Admin That would be nice. Something doesn't add up here. After 1st submission, any other deficiencies pointed out in the application other than quality of clinical studies should have been addressed, leaving the new clinical studies as the last piece of the re- submission. It's now week 4 for the clinical studies to be summarized and included in re-submission. Something else has to be contributing to the delay, hence the sell off. The markets have called Rob's bluff, his poker face isn't working anymore, he blinked and the markets caught it. Sadly it has come to this, so much initial promise.